Our proof-of-concept experiments showed that the co-application of pharmacological inhibitors of HER2 and TRPM7 had a synergistic antiproliferative effect on HER2-positive breast cancer SKBR3 cells but not HER2-deficient MDA-MB-231 cells. This evidence concerns the gene ERBB2 and breast cancer.